Skip to main content
Vicore Pharma Holding logo

Vicore Pharma Holding — Investor Relations & Filings

Ticker · VICO ISIN · SE0007577895 LEI · 549300KTNBPTZLF01130 ST Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2021-12-01 Major Shareholding Noti…
Country SE Sweden
Listing ST VICO

About Vicore Pharma Holding

https://vicorepharma.com/

Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), with disease-modifying potential. The company's research focuses on diseases where the AT2 receptor has a central role in stopping and reversing pathology. Its lead candidate, buloxibutid (C21), is a first-in-class, orally available small molecule ATRAG in clinical development for idiopathic pulmonary fibrosis (IPF). Vicore is also developing Almee™, a digital therapeutic based on cognitive behavioral therapy for the psychological impact of pulmonary fibrosis, which has received FDA Breakthrough Device Designation. The company utilizes its expertise in ATRAG chemistry and biology to build a pipeline primarily focused on respiratory diseases.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding by 'Handelsbanken Fonder AB' in 'Vicore Pharma Holding AB'. It explicitly shows the 'Before the transaction' and 'After the transaction' share counts and voting rights percentages, noting the 'Reason for major shareholding notification Sell'. The key indicator is the structure detailing changes in ownership percentages crossing a threshold (5% limit mentioned). This directly corresponds to the definition of a Major Shareholding Notification.
2021-12-01 English
Interim report July - September 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report Jul 1- Sep 30, 2021' for Vicore Pharma Holding AB. It contains comprehensive financial statements, including a summary of the period, financial overview, financial summary of the group, and an auditor's review report. It is a substantive quarterly financial report, not an announcement or a summary, and therefore fits the definition of an Interim/Quarterly Report (IR). Q3 2021
2021-11-04 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Vicore Pharma Holding AB covering the period from July 1 to September 30, 2021. It contains comprehensive financial statements, management commentary (VD-ord), business updates, and notes, which aligns with the definition of an Interim/Quarterly Report (IR). It is not an announcement of a report, as it contains the full content of the report itself. Q3 2021
2021-11-04 Swedish
Vicores C21 minskar långsiktiga lungskador efter COVID-19 i ATTRACT fas 2 uppföljningsstudien
Earnings Release Classification · 95% confidence The document is a press release dated November 2, 2021, announcing clinical trial results (ATTRACT follow-up study) regarding the drug C21's effect on long-term lung damage after COVID-19. It details specific data (HRCT scans, percentage of affected lung tissue), mentions ongoing Phase 3 trials (ATTRACT-3), and includes contact information and a concluding statement about regulatory disclosure obligations ('Denna information är sådan som Vicore Pharma Holding AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning'). This structure strongly indicates an initial announcement of financial/operational results, which aligns best with the Earnings Release (ER) category, even though the content is clinical trial results rather than quarterly financials. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or a transcript (CT). Since it is the primary announcement of key results, ER is the most appropriate fit among the provided options. FY 2021
2021-11-02 Swedish
Vicore’s C21 reduces long-term lung injury after COVID-19 in the ATTRACT Phase 2 extension study
Earnings Release Classification · 95% confidence The document is a press release announcing positive clinical trial results (Phase 2 extension study) for a drug candidate (C21) in treating long-term lung injury after COVID-19. It details specific data points (HRCT scans, percentage reduction in lung injury) and mentions ongoing and future trials (Phase 3 ATTRACT-3). The concluding paragraph states: "This information is such that Vicore Pharma Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation." This structure—a formal announcement of material, non-public information regarding clinical progress and regulatory compliance—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses purely on clinical trial results and business updates rather than comprehensive financial statements (10-K, IR) or management changes (MANG), and it is an initial announcement of results, 'ER' (Earnings Release) is the most appropriate fit, as these often include significant operational/clinical milestones for pharma companies, even outside of standard quarterly reporting periods. It is not a transcript (CT), a full report (AR/IR), or a proxy statement (DEF 14A/PSI). FY 2021
2021-11-02 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Vicore Pharma Holding AB covering the period from April 1 to June 30, 2021. It contains comprehensive financial statements, management commentary (VD-ord), business updates, and key performance indicators. It is not an announcement of a report, but the report itself, and it contains substantive financial data, fitting the definition of an Interim/Quarterly Report. H1 2021
2021-08-26 Swedish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.